[{"from": "human", "value": "Describe this molecule. [C][O][C][=C][Branch2][Ring1][O][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][=Branch1][C][=O][N][C][C][=Branch1][C][=C][C][C@H1][Ring1][=Branch1][C][=N][Ring1][=N][O][C][C][C][O][C][=C][Branch2][Ring1][=Branch2][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][N][=C][C@@H1][C][C][=Branch1][C][=C][C][N][Ring1][=Branch1][C][Ring1][N][=O][O][C]"}, {"from": "gpt", "value": "The molecule is a sequence-selective pyrrolobenzodiazepine (PBD) dimer with potential antineoplastic activity. Following intravenous administration, DNA minor groove binding agent SG2000 preferentially and covalently binds to purine-GATC-pyrimidine sequences, with the imine/carbinolamine moieties of SG2000 binding to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links and inhibits both DNA replication and gene transcription, which lead to the inhibition of cell growth. With a preference for binding to purine-GATC-pyrimidine sequences, SG2000 adducts do not appear to be susceptible to p53-mediated DNA excision repair."}]